Viatris Inc., a global healthcare company, and Idorsia Ltd announced they have entered into agreements for a significant worldwide research and development collaboration under which Viatris will receive exclusive worldwide development and commercialization rights to two phase 3 assets as well as the potential to add additional innovative assets in the future.
The collaboration includes selatogrel, a potential life-saving self-administered medicine for patients with a history of acute myocardial infarction (AMI) or heart attack, and builds on Viatris' existing global cardiovascular franchise and specialty infrastructure, as well as its knowledge, leadership, and distribution capabilities for self-administered medication for acute life-threatening conditions.
The collaboration also includes centimos, a novel immunology asset that can potentially be a first-in-class oral therapy for treating systemic lupus erythematosus (SLE), the most common form of lupus. Through lifecycle management, this asset has the potential for broad application across multiple autoimmune diseases in a specialist-driven category with attractive market dynamics for oral therapies. It could be a cornerstone asset in Viatris' immunology platform.
Viatris CEO Scott A. Smith said: "I am extremely pleased with our global research and development collaboration with Idorsia. We connect Idorsia's proven, highly productive drug development team and innovation engine with Viatris' strong worldwide infrastructure and experience to focus on two late-stage potential blockbuster assets with long-dated patent protection. We can execute on the potential of these global assets and any future assets as we work to build a more durable, predictable portfolio on the foundation of our strong base business. Selatogrel and centimos can become meaningful components of Viatris's business in the long term.
, CDSCO.jpg)
.jpg)